Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Liver International : Official Journal of the International Association for the Study of the Liver|December 2, 2025
Proton Beam Therapy Boosts Outcomes of Atezolizumab/Bevacizumab in Advanced Hepatocellular Carcinoma: A Propensity Score AnalysisYuan-Hung Kuo, Wei Teng, Po-Ting Lin, et al.International Journal of Radiation Oncology, Biology, Physics|October 1, 2023
Clinical and Dosimetric Results of Proton or Photon Radiation Therapy for Large (>5 cm) Hepatocellular Carcinoma: A Retrospective AnalysisRodney Cheng-En Hsieh, Ching-Hsin Lee, Hsiao-Chieh Huang, et al.Nature Communications|December 31, 2024
Rapid lightsheet fluorescence imaging of whole Drosophila brains at nanoscale resolution by potassium acrylate-based expansion microscopyXuejiao Tian, Tzu-Yang Lin, Po-Ting Lin, et al.Hepatology (Baltimore, Md.)|July 1, 2025
Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in hepatocellular carcinomaChien-Hao Huang, Wei-Ting Ku, Jayashri Mahalingam, et al.Liver Cancer|October 22, 2024
Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for OligoprogressionTsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, et al.Liver Cancer|July 9, 2026
Addition of Intra-Arterial Therapy to Immunotherapy Improves Outcomes in Unresectable Hepatocellular Carcinoma: Taiwan Multicenter Cohort StudyTeng-Yu Lee, Pei-Chang Lee, Ying-Chun Shen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2024
Clinical Outcomes and Histologic Findings of Patients With Hepatocellular Carcinoma With Durable Partial Response or Durable Stable Disease After Receiving Atezolizumab Plus BevacizumabYing-Chun Shen, Tsung-Hao Liu, Alan Nicholas, et al.European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.Journal of Hepatology|June 15, 2026
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinomaPasquale Lombardi, Erik Ramon-Gil, Rabial Q Raja, et al.Pageof 7